GlassScriptPhysician profile
John Savooji
NPI 1447684808
$3,523.96
in general payments reported to CMS, 2019-2025
36 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.33 · 2021: $541 · 2022: $362 · 2023: $864 · 2024: $1,588 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,575 · Food and Beverage: $1,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,575.00 |
| Food and Beverage | $1,027.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,671.77 | 2020-2024 | Lynparza, Truqap, Imfinzi |
| Janssen Biotech, INC. | $203.82 | 2021 | |
| Histosonics, INC. | $150.28 | 2025 | |
| Merck Sharp & Dohme LLC | $145.59 | 2021-2023 | Keytruda |
| Novartis Pharmaceuticals Corporation | $131.15 | 2021-2023 | |
| Genentech USA, INC. | $118.27 | 2022-2023 | Lunsumio, Tecentriq, Polivy |
| Amgen INC. | $109.04 | 2021-2023 | Blincyto, Kyprolis |
| Celgene Corporation | $97.74 | 2022-2024 | Reblozyl, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $65.02 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $58.66 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $53.50 | 2022-2023 | Rezlidhia, Tavalisse |
| Genzyme Corporation | $50.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.28 | 2023 | Vonvendi, Alunbrig |
| Pfizer INC. | $46.08 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $45.91 | 2023 | Xpovio |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $44.90 | 2022-2023 | Opdivo |
| Kite Pharma, INC. | $43.03 | 2023 | Yescarta |
| Daiichi Sankyo INC. | $39.64 | 2022-2023 | Injectafer |
| Adaptive Biotechnologies Corporation | $36.73 | 2022-2023 | Clonoseq |
| Servier Pharmaceuticals LLC | $34.85 | 2022-2023 | |
| Emd Serono, INC. | $34.19 | 2023 | Bavencio |
| Kyowa Kirin, INC. | $30.35 | 2022-2023 | Poteligeo |
| Foundation Medicine, INC. | $30.35 | 2023 | |
| Beigene USA, INC. | $29.68 | 2023 | Brukinsa |
| Ge Healthcare | $21.97 | 2021 | |
| Puma Biotechnology, INC. | $21.36 | 2023 | |
| Global Blood Therapeutics, INC. | $19.95 | 2021 | |
| Abbvie INC. | $19.30 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.18 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.59 | 2023 | Libtayo |
| Eisai INC. | $17.26 | 2023 | |
| Glaxosmithkline, LLC. | $16.33 | 2023 | Shingrix, Zejula, Jemperli |
| Sumitomo Pharma America, INC. | $15.30 | 2023 | Orgovyx |
| Array Biopharma INC | $12.97 | 2023 | Mektovi, Braftovi |
| Blueprint Medicines Corporation | $12.69 | 2022 | |
| Gilead Sciences, INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Savooji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.